Ibrance Real World Insights [IRIS]
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/6/2019 |
| Start Date: | June 12, 2017 |
| End Date: | September 30, 2019 |
| Contact: | Pfizer CT.gov Call Center |
| Email: | ClinicalTrials.gov_Inquiries@pfizer.com |
| Phone: | 1-800-718-1021 |
TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS
To describe patient demographics, clinical characteristics, treatment patterns and clinical
outcomes of adult female patients who have received palbociclib combination treatments in
line with regional licensed indications in real world settings across multiple countries.
outcomes of adult female patients who have received palbociclib combination treatments in
line with regional licensed indications in real world settings across multiple countries.
INCLUSION CRITERIA
- ≥18 years old
- HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
- Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus
fulvestrant in line with the licenced indication(s)
- No prior or current enrolment in an interventional clinical trial for ABC/MBC
- Minimum of three months of follow up data since palbociclib with fulvestrant
initiation, or minimum of six months of follow up data since palbociclib with
letrozole/aromatase inhibitor initiation (core medical record review)
- Minimum of three months of follow up data since palbociclib initiation (interim
medical record review)
We found this trial at
1
site
Click here to add this to my saved trials
